OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
May 07, 2021
Vectura and Inspira Pharmaceuticals have joined forces to develop a potential inhaled therapy for COVID-19.
March 10, 2021
The expansion plans to increase Vectura’s DPI dosage form development, specifically its unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs.
December 08, 2020
A development agreement will study inhaled formulations of cannabinoid-based drug product for central nervous system diseases.
September 14, 2020
Vectura will support the product from Phase I through to commercial launch.
September 02, 2020
Creating an inhaled formulation is one way in which improved efficacy or added value can be achieved in projects to repurpose or reposition existing drugs.
September 01, 2020
The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.
February 12, 2020
Inhalation drug delivery company Vectura announces new organizational structure to drive innovation, customer focus, and growth.
June 02, 2019
A simple, one-part DPI aims to make inhalation drug treatment more accessible and affordable.
May 15, 2019
Consider both the device characteristics and the powder properties when developing a DPI combination product.
May 09, 2019
Recipharm Inhalation Solutions is an integrated service for inhalation products.